Sign in to view content

Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in Diabetic Macular Edema: 36-Week Results From the Phase 2 BOULEVARD Clinical Trial

Rishi P. Singh, MD

Video
Published 2018

Related

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
Safety and Efficacy of Retropupillary Iris Claw Intraocular Lens Implant in Aphakia With Inadequate Capsular Support
Aniruddha Maiti, MBBS DO DNB FRVS FICO MRCS FACS FASRS FRCOphth
Annual Meeting Talks
2018
A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018

Category: Diabetic Retinopathy

See more